Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Gastrointestinal SPOREs

The Specialized Programs of Research Excellence (SPOREs) in Gastrointestinal (GI) cancers focus on translational research in the gastrointestinal system and include cancers of the colon, rectum, stomach, esophagus, small intestine, liver, gallbladder, and other digestive organs. Over 362,200 newly diagnosed cases of cancer in the digestive system and 174,520 deaths are expected in the United States in the year 2025, the American Cancer Society estimates. Colorectal and colon cancers are particularly prevalent and represented 8.7% of all new cancer cases in the U.S. in 2024, while these cancers were responsible for 53,010 deaths. Currently, GI SPOREs focus on cancers of the colon, rectum, esophagus, stomach, liver, and pancreas, which account for the majority of new diagnoses.

MDACC Gastrointestinal Cancer SPORE

Vanderbilt-Ingram Cancer Center Gastrointestinal Cancer SPORE

DFHCC Gastrointestinal Cancer SPORE

FHCRC Gastrointestinal Cancer SPORE

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Gastrointestinal SPOREs was originally published by the National Cancer Institute.”

Email